Replies to post #5108 on Insmed Inc (INSM)

[read_this_n0w]

Buyout 50% premium is normal for established companies with regular revenue, not for promising biotech
Its all about potential revenue vs market cap.

a buyout at 50%+ from current levelslevels would never work at this moment for a promising biotech such as insm,

better example is RNAI there
first climb from 2,50$ to 5,00$, than a 13$ takeover bid
http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=OBR&Date=20061030&ID=6149....
just one example

Very strongly disagree with wklnew there